Ibrexafungerp citrate | Radio Compass News | PharmaCompass.com

Grow Your Pharma Business Digitally

X

Market Place

Sourcing support

Sourcing Support

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

All News Ibrexafungerp Citrate

Enforcement Report - Week of October 18, 2023

18 Oct 2023 //

FDA

SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME

27 Sep 2023 //

GLOBENEWSWIRE

SCYNEXIS and Hansoh Announce NMPA Acceptance of NDA for Ibrexafungerp

20 Jul 2023 //

GLOBENEWSWIRE

SCYNEXIS Achieves $25M GSK Development Milestone

21 Jun 2023 //

CONTRACTPHARMA

SCYNEXIS Reports Closing of Agreement with GSK for BREXAFEMME

12 May 2023 //

GLOBENEWSWIRE

Scynexis to Present Ibrexafungerp Data at the 33rd Annual ECCMID April 15-18

13 Apr 2023 //

GLOBENEWSWIRE

GSK and Scynexis announce an exclusive agreement to commercialise Brexafemme

31 Mar 2023 //

PRESS RELEASE

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMMEÂ®

01 Dec 2022 //

GLOBENEWSWIRE

BARDA Invests in Development of Antifungal Treatments

18 Nov 2022 //

CONTRACTPHARMA

SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp

07 Nov 2022 //

GLOBENEWSWIRE

SCYNEXIS Presents Positive Interim Data of Ibrexafungerp Ongoing Phase 3

08 Sep 2022 //

GLOBENEWSWIRE

SCYNEXIS Presents Positive Data from PIII CANDLE Study of Oral Ibrexafungerp

04 Aug 2022 //

GLOBENEWSWIRE

SCYNEXIS Presents Positive Data from PIII CANDLE Nested Study of Ibrexafungerp

19 Jul 2022 //

GLOBENEWSWIRE

SCYNEXIS to Present Data from CANDLE Nested Sub-Study of Ibrexafungerp

14 Jul 2022 //

GLOBENEWSWIRE

SCYNEXIS Initiates New PIIIb Study (VANQUISH) for Oral Ibrexafungerp in WC

23 Jun 2022 //

GLOBENEWSWIRE

SCYNEXIS Submits sNDA of BREXAFEMME to FDA for Vaginal Yeast Infections

08 Jun 2022 //

GLOBENEWSWIRE

SCYNEXIS Presents Data Analyses Showing Ibrexafungerp`s Potential

27 Apr 2022 //

GLOBENEWSWIRE

SCYNEXIS Secures Addn Commercial Insurance Formulary Coverage for BREXAFEMME

19 Apr 2022 //

GLOBENEWSWIRE

SCYNEXIS Announces Positive Results from Phase 3 CANDLE Study of Ibrexafungerp

10 Feb 2022 //

GLOBENEWSWIRE

BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary

20 Dec 2021 //

GLOBENEWSWIRE

SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL

29 Nov 2021 //

GLOBENEWSWIRE

SCYNEXIS Announces Successful Completion of Phase 1 Trial (IV) Ibrexafungerp

09 Nov 2021 //

GLOBENEWSWIRE

SCYNEXIS Announces Preclinical Data at the 10th Trends Medical Mycology Meeting

11 Oct 2021 //

GLOBENEWSWIRE

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing

29 Sep 2021 //

GLOBENEWSWIRE

SCYNEXIS Announces U.S. Availability of BREXAFEMME

22 Sep 2021 //

GLOBENEWSWIRE

SCYNEXIS Announces Hansoh`s Application to NMPA for Ph3 Trial of Ibrexafungerp

13 Sep 2021 //

GLOBENEWSWIRE

SCYNEXIS Reports Second Quarter 2021 Financial Results and Corporate Update

16 Aug 2021 //

GLOBENEWSWIRE

SCYNEXIS Confirms BREXAFEMME Qualifies for 10 Years of Regulatory Exclusivity

09 Jun 2021 //

GLOBENEWSWIRE

SCYNEXIS Announces FDA Approval of BREXAFEMME®

02 Jun 2021 //

PRESS RELEASE

SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation

10 Dec 2020 //

SCYNEXIS

SCYNEXIS Announces FDA Acceptance and Priority Review of NDA

07 Dec 2020 //

FIRSTWORLDPHARMA

SCYNEXIS to Present Data Supporting the Efficacy of Ibrexafungerp

21 Oct 2020 //

PRESS RELEASE

SCYNEXIS Reports Successful Completion Pre-NDA Meetings with FDA Ibrexafungerp

29 Jul 2020 //

GLOBENEWSWIRE

SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Ibrexafungerp

22 Jul 2020 //

GLOBENEWSWIRE

SCYNEXIS Announces Six Abstracts Pub by 30th ECCMID Highlighting Ibrexafungerp

06 May 2020 //

SCYNEXIS

Scynexis` new antifungal delivers in yeast infection phase 3

21 Apr 2020 //

PRESS RELEASE

SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles

05 Mar 2020 //

GLOBENEWSWIRE

Scynexis completes patient enrollment for women’s health phase 3 study

13 Feb 2020 //

PHARMIWEB